ClinVar Miner

Submissions for variant NM_002968.3(SALL1):c.420del (p.Ser141fs)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001203386 SCV001374549 pathogenic Townes syndrome 2019-07-31 criteria provided, single submitter clinical testing This sequence change results in a premature translational stop signal in the SALL1 gene (p.Ser141Alafs*42). This variant is not present in population databases (ExAC no frequency). This variant has been observed in individuals with clinical features of Townes-Brocks syndrome, including at least one individual where the variant was reported de novo (PMID: 9973281, Invitae). This variant is also known as c.419delC in the literature. Truncating variants in the SALL1 gene are known to cause Townes-Brocks syndrome by haploinsufficiency (PMID: 16429401, 22308078) or by a dominant negative mechanism (PMID: 29395072). Truncations both upstream (p.Thr105Glnfs*78) and downstream (p.Arg260*) of this variant have been shown to be clinically significant and are consistent with a dominant negative mechanism (PMID: 17221874, 16088922, Invitae). This suggests that deletion of this region of the SALL1 protein is causative of disease. For these reasons, this variant has been classified as Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.